Biotron Ltd
ASX:BIT

Watchlist Manager
Biotron Ltd Logo
Biotron Ltd
ASX:BIT
Watchlist
Price: 0.002 AUD
Market Cap: 2.7m AUD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

BIT doesn't have a meaningful market cap.

The Relative Value of one BIT stock under the Base Case scenario is 0.016 AUD. Compared to the current market price of 0.002 AUD, Biotron Ltd is Undervalued by 87%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BIT Relative Value
Base Case
0.016 AUD
Undervaluation 87%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
95
vs Industry
71
Median 3Y
24.2
Median 5Y
45.8
Industry
7.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-18.6
Median 5Y
-22.7
Industry
23
More Details
14.6
P/OCF
P/OCF
Price to OCF
14.6
vs History
9
vs Industry
6
Median 3Y
-17.4
Median 5Y
-22.9
Industry
19.4
More Details
16
P/FCFE
P/FCFE
Price to FCFE
16
vs History
9
vs Industry
6
Median 3Y
-17.3
Median 5Y
-22.6
Industry
23.1
More Details
5.8
P/B
P/B
Price to Book Value
5.8
vs History
88
vs Industry
8
Median 3Y
13
Median 5Y
17.3
Industry
2.6
More Details
1
EV/S
EV/S
Enterprise Value to Sales
1
vs History
95
vs Industry
63
Median 3Y
24
Median 5Y
43.9
Industry
7.5
More Details
24.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
24.4
vs History
19
vs Industry
13
Median 3Y
-19.9
Median 5Y
-37.4
Industry
9.4
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-20.4
Industry
4.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-20.4
Industry
4.5
More Details
9.8
EV/OCF
EV/OCF
Enterprise Value to OCF
9.8
vs History
9
vs Industry
7
Median 3Y
-17.3
Median 5Y
-21
Industry
5.2
More Details
9.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
9.9
vs History
9
vs Industry
6
Median 3Y
-17.3
Median 5Y
-21
Industry
3.7
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
14
Median 3Y
-168.3
Median 5Y
-246.5
Industry
4.8
More Details

Multiples Across Competitors

BIT Competitors Multiples
Biotron Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Biotron Ltd
ASX:BIT
2.7m AUD 1.5 -1.9 -1.2 -1.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 698 702.5 -164 917.8 -200 262.8 -197 977.5
US
Abbvie Inc
NYSE:ABBV
334.7B USD 5.8 80.6 15.3 22.7
US
Amgen Inc
NASDAQ:AMGN
157.8B USD 4.6 26.6 14.3 23.6
US
Gilead Sciences Inc
NASDAQ:GILD
137.1B USD 4.8 23 10 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116B USD 10.5 -117.3 24.9 26.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 030.3 -518.1 -564.1 -549.1
AU
CSL Ltd
ASX:CSL
117.4B AUD 5 27.9 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
56.6B USD 4 12.6 11.2 12.6
US
Seagen Inc
F:SGT
39.3B EUR 19.6 -60 -64.6 -58.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
39.4B USD 16.8 -146.1 -653.9 -327.7
P/S Multiple
Revenue Growth P/S to Growth
AU
Biotron Ltd
ASX:BIT
Average P/S: 3 154 618.7
1.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 698 702.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.5
10%
1
US
E
Epizyme Inc
F:EPE
2 030.3
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4
4%
1
US
S
Seagen Inc
F:SGT
19.6
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.8
29%
0.6
P/E Multiple
Earnings Growth PEG
AU
Biotron Ltd
ASX:BIT
Average P/E: 34.1
Negative Multiple: -1.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -164 917.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.6
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.6
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -117.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.1 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
7%
1.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -60 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -146.1 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Biotron Ltd
ASX:BIT
Average EV/EBITDA: 15.5
Negative Multiple: -1.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 262.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.3
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.2
11%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -64.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -653.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Biotron Ltd
ASX:BIT
Average EV/EBIT: 20
Negative Multiple: -1.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 977.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.6
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -549.1 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.6
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -327.7 N/A N/A

See Also

Summary
BIT intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIT stock valuation using valuation multiples.
Wall Street Estimates
BIT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 260,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.